vimarsana.com

Page 32 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mediterranean diet may protect against Alzheimer s disease, suggests study | Dumbarton and Vale of Leven Reporter

The study looked at abnormal proteins called amyloid and tau. Amyloid is a protein that forms into plaques, while tau is a protein that forms into tangles. They are both found in the brains of people with Alzheimer’s disease but may also be found in the brains of older people with normal cognition. The Mediterranean diet includes a high intake of vegetables, legumes, fruits, cereals, fish and monounsaturated fatty acids such as olive oil, and low intake of saturated fatty acids, dairy products and meat. Study author Tommaso Ballarini, of the German Centre for Neurodegenerative Diseases (DZNE) in Bonn, Germany, said: “Our study suggests that eating a diet that’s high in unsaturated fats, fish, fruits and vegetables, and low in dairy and red meat may actually protect your brain from the protein build-up that can lead to memory loss and dementia.

Cognitive Assessment And Training Market Size Expected To Reach $15 65 Billion In 2028

Share this article Share this article PALM BEACH, Fla., May 4, 2021 /PRNewswire/  Cognitive assessment and training solutions and programs have been witnessing increasing demand due to rise in literacy rates and improved economic conditions among a growing population, especially in developing economies. These programs and tests help students and other users to determine their psychological functions and pace at which information can be processed by the brain. Tests are carried out to determine a person s ability to learn by identifying their strengths and weaknesses, and then, appropriate assessment and training helps them to overcome their weaknesses. COVID-19 has increased the need for social distancing, which has spurred adoption of online cognitive tests. The pandemic resulted in various organizations shifting towards adoption of digital technologies as well as online operations. Rapid adoption of smartphones in cognitive assessment and clinical research for data collection,

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results Continued Zepzelca Growth Across Second-Line SCLC Setting Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition 23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020 2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.